Key result
NT-pro-BNP serves as a reliable diagnostic and prognostic marker for pulmonary hypertension and congenital heart diseases in pediatric patients.
Why the study?
To analyze recent studies evaluating the diagnostic and prognostic role of NT-pro-BNP in pediatric cardiac patients with pulmonary hypertension.
Does NT-pro-BNP assessment improve diagnostic and prognostic evaluation in pediatric patients with congenital heart disease and pulmonary hypertension?
Does NT-pro-BNP assessment improve diagnostic and prognostic evaluation in pediatric patients with congenital heart disease and pulmonary hypertension?
NT-pro-BNP serves as a reliable universal marker for diagnosing and predicting outcomes in pediatric cardiovascular pathology, including congenital heart disease and pulmonary hypertension.
Supports NT-proBNP integration into pediatric CHD and PH evaluation; reinforces consensus from prior studies.
Objective: Several studies showed that N-terminal pro-brain type natriuretic peptide (NT-pro-BNP) as the reliable marker both in diagnostic and prognostic workup of pediatric patients with congenital heart disease complicated by pulmonary hypertension. Furthermore, it has well assisted both in therapeutic and surgical management of children with congenital heart diseases. In this review, we aimed to analyze recent studies concerning the role of the NT-pro-BNP in pediatric cardiac patients with pulmonary hypertension. Methods: PubMed, Cochrane, Science Direct and Google Scholar databases were used with the searching of the following words: “amino terminal pro brain type natriuretic peptide”, “pediatric pulmonary hypertension”, “congenital heart diseases”, emphasizing on original research articles published within recent 15 years and in English language. We critically analyzed and summarized the retrieved studies. Conclusion: NT-pro-BNP remains as the reliable diagnostic and prognostic marker of pulmonary hypertension and congenital heart diseases in pediatric patients. NT-pro-BNP and BNP remain as the universal marker of cardiovascular pathology in pediatric population. Improvement of their effectiveness in diagnostic workup in patients with CHD and PH undergoing surgery needs further clarification.
No takes yet. Share an insight, caveat, or question.
Tilemanbetova et al. (2021) conducted a review in Pediatric cardiac diseases and pulmonary hypertension. NT-pro-BNP assay was evaluated. NT-pro-BNP serves as a reliable diagnostic and prognostic marker for pulmonary hypertension and congenital heart diseases in pediatric patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: